Sichuan Baili Pharmaceutical Co., Ltd.
baili-pharm.comTotal trials
113
Active
108
Phase 3
26
Total enrollment
20,918
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 40 of 63 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| BL-B01D1 | — | — | — | 38 | |||
| BL-M07D1 | — | — | — | 17 | |||
| SI-B001 | — | — | — | 11 | |||
| Docetaxel | — | — | — | — | 8 | ||
| Capecitabine | — | — | — | — | — | 5 | |
| Paclitaxel | — | — | — | — | 5 | ||
| Pembrolizumab | — | — | — | — | 5 | ||
| Gemcitabine | — | — | — | — | — | 3 | |
| BL-M11D1 | — | — | — | 3 | |||
| Pertuzumab | — | — | — | — | 3 | ||
| Irinotecan Hydrochloride | — | — | — | — | — | 3 | |
| Irinotecan | — | — | — | — | 3 | ||
| Eribulin | — | — | — | — | — | 2 | |
| Vinorelbine | — | — | — | — | — | 2 | |
| Topotecan | — | — | — | — | — | 2 | |
| T-DM1 | — | — | — | — | — | 2 | |
| Tislelizumab | — | — | — | — | — | 2 | |
| Cisplatin | — | — | — | — | — | 2 | |
| Osimertinib | — | — | — | — | — | 2 | |
| Carboplatin | — | — | — | — | — | 2 | |
| Oxaliplatin | — | — | — | — | — | 2 | |
| Calcium levofolinate | — | — | — | — | — | 2 | |
| Fluorouracil | — | — | — | — | — | 2 | |
| Irinotecan Hydrochloride Liposome | — | — | — | — | — | 2 | |
| BL-M05D1 | — | — | — | — | 2 | ||
| Liposomal doxorubicin, Paclitaxel or Topotecan | — | — | — | — | — | 1 | |
| Liposomal Doxorubicin | — | — | — | — | — | 1 | |
| Pemetrexed+Cisplatin or Carboplatin | — | — | — | — | — | 1 | |
| 5-Fluorouracil | — | — | — | — | — | 1 | |
| Capecitabine, Eribulin, Gemcitabine, Paclitaxel, or Albumin paclitaxel | — | — | — | — | — | 1 | |
| Etoposide | — | — | — | — | — | 1 | |
| Investigator's choice of chemotherapy | — | — | — | — | — | 1 | |
| Pemetrexed | — | — | — | — | — | 1 | |
| Trastuzumab | — | — | — | — | — | 1 | |
| Cytarabine | — | — | — | — | — | 1 | |
| Daunorubicin | — | — | — | — | — | 1 | |
| Venetoclax | — | — | — | — | — | 1 | |
| Azacitidine | — | — | — | — | — | 1 | |
| Docetaxel or Paclitaxel | — | — | — | — | — | 1 | |
| SI-B003 | — | — | — | — | 11 |
23 more active programs hidden
Next readouts
- 2025-12
- 2025-12
- 2025-12
- 2025-12
- 2025-12
- 2025-12
- 2025-12
- 2025-12
- 2025-12
- 2025-12
Top conditions
- Solid Tumor23
- Non-small Cell Lung Cancer13
- Breast Cancer10
- Head and Neck Squamous Cell Carcinoma7
- HER2-positive Breast Cancer5
- Solid Tumors4
- Gastrointestinal Tumors3
- Nasopharyngeal Carcinoma3
Frequently asked questions about Sichuan Baili Pharmaceutical Co., Ltd.
- How many clinical trials does Sichuan Baili Pharmaceutical Co., Ltd. have on ClinicalTrials.gov?
- Sichuan Baili Pharmaceutical Co., Ltd. is listed as the lead sponsor on 113 clinical trials in ClinicalTrials.gov, 108 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Sichuan Baili Pharmaceutical Co., Ltd.'s trials are in Phase 3?
- 26 of Sichuan Baili Pharmaceutical Co., Ltd.'s trials are in Phase 3, spread across 63 active drug programs.
- What therapeutic areas does Sichuan Baili Pharmaceutical Co., Ltd. focus on?
- Sichuan Baili Pharmaceutical Co., Ltd.'s most-studied conditions on ClinicalTrials.gov are Solid Tumor, Non-small Cell Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma, HER2-positive Breast Cancer.
- When are Sichuan Baili Pharmaceutical Co., Ltd.'s next clinical trial readouts?
- Sichuan Baili Pharmaceutical Co., Ltd. has 10 upcoming primary-completion readouts tracked here; the soonest is “SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.”, expected around 2025-12.